Explore /
Poster
/ Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints.

Authors

Benjamin Louis Maughan

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Benjamin Louis Maughan , Andrew W Hahn , Roberto Nussenzveig , John Hoffman , Kathryn Morton , Sumati Gupta , Julia Anne Batten , Jared Thorley , Josiah Hawks , Victor Sacristan Santos , Gayatri Nachaegari , Xuechen Wang , Kenneth M. Boucher , Benjamin Haaland , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02199197

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 125)

Abstract #

125

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2021 Genitourinary Cancers Symposium

$Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.$

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.

First Author: Adam Kessel

Poster

2018 ASCO Annual Meeting

$Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer (mCRPC).$